Cowen And Company, LLC Immunic, Inc. Transaction History

Cowen And Company, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.97 - $1.6 $307,547 - $507,294	317,059 New	317,059 $475,000
Q3 2023 Nov 09, 2023	SELL	$1.35 - $2.87 $55,074 - $117,084	-40,796 Reduced 11.4%	317,059 $466,000
Q1 2023 May 09, 2023	SELL	$1.35 - $2.87 $584,778 - $1.24 Million	-433,169 Reduced 54.76%	357,855 $533,000
Q4 2022 Feb 09, 2023	SELL	$1.13 - $1.51 $462,923 - $618,597	-409,667 Reduced 34.12%	791,024 $1.11 Million
Q2 2022 Aug 05, 2022	SELL	$3.13 - $12.25 $176,704 - $691,573	-56,455 Reduced 4.49%	1,200,691 $4.17 Million

Q1 2022 May 16, 2022	BUY	$9.54 - $14.26 $9.55 Million - $14.3 Million	1,001,291 Added 391.35%	1,257,146 $14.2 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $1.88 Million - $2.62 Million	255,855 New	255,855 $2.45 Million

57.6M

600

254K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $33.9M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.